Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated strong revenue growth, with a year-over-year increase of 57% in its core revenue, supported by a higher mix of new prescriptions in the pharmacy channel than anticipated. The company has revised its revenue projections upward for 2025 and 2026, anticipating $97.5 million and $136 million respectively, while also indicating continued enhancements in quarterly revenue estimates due to strong new prescription momentum. Furthermore, management has raised its fiscal year 2025 revenue guidance by over $6 million, reflecting confidence in sustained premium growth, estimated at a compound annual growth rate of 30-40% from 2024 to 2028.

Bears say

Beta Bionics faces several key challenges that contribute to a negative outlook on its stock, primarily related to its flagship iLet Bionic Pancreas product. The company risks failing to secure significant market share and may struggle with sustained penetration into the pharmacy channel, which could adversely affect revenue and profitability projections. Additionally, potential delays in clinical development and regulatory approvals could hinder adoption rates, alongside possible shareholder dilution from capital needs and unfavorable Medicare reimbursement proposals that could further impact the company's financial performance.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.